Skip to main content

Table 2 Virologic responses of the different fibrosis groups

From: Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study

Response Overall Group A Group B  
HCV genotype n/N (%) n/N (%) n/N (%) p-value
RVR 102/151 (67.5) 21/36 (58.3) 81/115 (70.4) 0.176
 1 50/91 (54.9) 9/22 (40.9) 41/69 (59.4) 0.129
 Non-1 52/60 (86.7) 12/14 (85.7) 40/46 (87) 0.9.5
cEVR 140/154 (90.9) 30/37 (81.1) 110/117 (94) 0.017
 1 77/91 (84.6) 15/22 (68.2) 62/69 (89.9) 0.014
 Non-1 63/63 (100) 15/15 (100) 48/48 (100)
ETR 148/168 (88.1) 36/42 (85.7) 112/126 (88.9) 0.582
 1 84/100 (84) 21/25 (84) 63/75 (84) 1
 Non-1 64/68 (94.1) 15/17 (88.2) 49/51 (96.1) 0.234
SVR 98/168 (58.3) 19/42 (45.2) 79/126 (69.7) 0.047
 1 46/100 (46) 6/25 (24)* 40/75 (53.3)** 0.011
 Non-1 53/68 (76.5) 13/17 (76.5)* 39/51 (76.5)** 1.0
SVR (with RVR) 77/102 (75.5) 14/21 (66.7) 63/81 (77.8) 0.291
 1 35/50 (70) 4/9 (44.4) 31/41 (75.6) 0.065
 Non-1 42/52 (80.8) 10/12 (83.3) 32/40 (80) 0.797
Relapse 50/148 (33.8) 17/36 (47.2) 33/112 (29.5) 0.05
 1 38/84 (45.2)# 15/21 (71.4) 23/63 (36.5) 0.005
 Non-1 12/64 (18.8)# 2/15 (13.3) 10/49 (20.4) 0.539
Discontinuation 13/168 (7.7) 6/42 (14.3) 7/126 (5.6) 0.067
 1 8/100 (8) 3/25 (12) 5/75 (6.7) 0.395
 Non-1 5/68 (7.4) 3/17 (17.6) 2/51 (3.9) 0.06
  1. n, number of patients with response; N, total number of patients in the group.
  2. HCV, hepatitis C virus; RVR, rapid virologic response; cEVR, complete early virologic response; ETR, end of treatment response; SVR, sustained virologic response.
  3. Group A, patients with Ishak fibrosis score 4–6.
  4. Group B, patients with Ishak fibrosis score 0–3.
  5. *p = 0.001; **p = 0.008, #p = 0.001.